Publications 2022

Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on 18F-DCFPyL PET/CT Scans 

Garg T, Werner RA, Chung HW, Khatri W, Pienta KJ, Pomper MG, Gorin MA, Saad E, Rowe SP, 2022 Dec Tomography 8 2639-2647

The SARS-CoV-2 spike protein binds and modulates estrogen receptors 

Solis O, Beccari AR, Iaconis D, Talarico C, Ruiz-Bedoya CA, Nwachukwu JC, Cimini A, Castelli V, Bertini R, Montopoli M, Cocetta V, Borocci S, Prandi IG, Flavahan K, Bahr M, Napiorkowski A, Chillemi G, Ooka M, Yang X, Zhang S, Xia M, Zheng W, Bonaventura J, Pomper MG, Hooper JE, Morales M, Rosenberg AZ, Nettles KW, Jain SK, Allegretti M, Michaelides M, 2022 Dec Science Advances 8

Automated lesion detection of breast cancer in [18F]FDG PET/CT using a novel AI-Based workflow 

Leal JP, Rowe SP, Stearns V, Connolly RM, Vaklavas C, Liu MC, Storniolo AM, Wahl RL, Pomper MG, Solnes LB, 2022 Nov Frontiers in Oncology 12

Hetero-bivalent agents targeting FAP and PSMA 

Boinapally S, Lisok A, Lofland G, Minn I, Yan Y, Jiang Z, Shin MJ, Merino VF, Zheng L, Brayton C, Pomper MG, Banerjee SR, 2022 Nov European Journal of Nuclear Medicine and Molecular Imaging 49 4369-4381

Correction to: Hetero-bivalent agents targeting FAP and PSMA 

Boinapally S, Lisok A, Lofland G, Minn I, Yan Y, Jiang Z, Shin MJ, Merino VF, Zheng L, Brayton C, Pomper MG, Banerjee SR, 2022 Nov European Journal of Nuclear Medicine and Molecular Imaging 49 4755

Photorealistic three-dimensional visualization of fusion datasets: cinematic rendering of PET/CT 

Rowe SP, Pomper MG, Leal JP, Schneider R, Krüger S, Chu LC, Fishman EK, 2022 Nov Abdominal Radiology 47 3916-3920

PET/CT imaging of CSF1R in a mouse model of tuberculosis 

Foss CA, Ordonez AA, Naik R, Das D, Hall A, Wu Y, Dannals RF, Jain SK, Pomper MG, Horti AG, 2022 Oct European Journal of Nuclear Medicine and Molecular Imaging 49 4088-4096

18F-Labeled Radiotracers for Prostate-specific Membrane Antigen: Historical Perspective and Future Directions 

Rowe SP, Salavati A, Werner RA, Pienta KJ, Gorin MA, Pomper MG, Solnes LB, 2022 Oct PET Clinics 17 585-593

System-level optimization in spectroscopic photoacoustic imaging of prostate cancer 

Wu Y, Kang J, Lesniak WG, Lisok A, Zhang HK, Taylor RH, Pomper MG, Boctor EM, 2022 Sep Photoacoustics 27

PSMA-specific degradable dextran for multiplexed immunotargeted siRNA therapeutics against prostate cancer 

Chen Z, Krishnamachary B, Mironchik Y, Ray Banerjee S, Pomper MG, Bhujwalla ZM, 2022 Aug Nanoscale 14 14014-14022

Rechallenge with Additional Doses of 177Lu-DOTATOC after Failure of Maintenance Therapy with Cold Somatostatin Analogs 

Weich A, Werner RA, Serfling SE, Solnes LB, Pomper MG, Buck AK, Higuchi T, Rowe SP, 2022 Aug Clinical Nuclear Medicine 47 719-720

Generation of Digital Brain Phantom for Machine Learning Application of Dopamine Transporter Radionuclide Imaging 

Shao W, Leung KH, Xu J, Coughlin JM, Pomper MG, Du Y, 2022 Aug Diagnostics 12

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers 

Weich A, Higuchi T, Bundschuh RA, Lapa C, Serfling SE, Rowe SP, Pomper MG, Herrmann K, Buck AK, Derlin T, Werner RA, 2022 Aug Molecular Imaging and Biology 24 631-640

Molecular imaging in oncology: Current impact and future directions 

Rowe SP, Pomper MG, 2022 Jul CA Cancer Journal for Clinicians 72 333-352

Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR-and PSMA-Directed Endoradiotherapy 

Hasenauer N, Higuchi T, Deschler-Baier B, Hartrampf PE, Pomper MG, Rowe SP, Fassnacht M, Buck AK, Werner RA, 2022 Jul Clinical Nuclear Medicine 47 651-652

SPECT and PET Radiotracers in Renal Imaging 

Werner RA, Pomper MG, Buck AK, Rowe SP, Higuchi T, 2022 Jul Seminars in Nuclear Medicine 52 406-418

Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma 

Vaughan HJ, Zamboni CG, Hassan LF, Radant NP, Jacob D, Mease RC, Minn I, Tzeng SY, Gabrielson KL, Bhardwaj P, Guo X, Francisco D, Pomper MG, Green JJ, 2022 Jul Science Advances 8

Targeted Theranostic 111In/Lu-Nanotexaphyrin for SPECT Imaging and Photodynamic Therapy 

Cheng MH, Overchuk M, Rajora MA, Lou JW, Chen Y, Pomper MG, Chen J, Zheng G, 2022 Jun Molecular Pharmaceutics 19 1803-1813

DCFPyL PET/CT for Imaging of Prostate Cancer 

Rowe SP, Buck A, Bundschuh RA, Lapa C, Serfling SE, Derlin T, Higuchi T, Gorin MA, Pomper MG, Werner RA, 2022 Jun Nuklearmedizin - NuclearMedicine 61 240-246

Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From the AJR Special Series on Imaging of Inflammation 

Sheikhbahaei S, Marcus CV, Sadaghiani MS, Rowe SP, Pomper MG, Solnes LB, 2022 Jun American Journal of Roentgenology 218 940-952

177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis 

Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Gorin MA, Solnes LB, Rowe SP, 2022 May Prostate 82 826-835

First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients 

Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, Pomper MG, Zhu H, Zhao J, Yang Z, Li N, 2022 Apr Journal of Nuclear Medicine 63 536-542

An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications 

Lesniak WG, Azad BB, Chatterjee S, Lisok A, Pomper MG, 2022 Mar Pharmaceutics 14

A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents 

Chen Y, Minn I, Rowe SP, Lisok A, Chatterjee S, Brummet M, Banerjee SR, Mease RC, Pomper MG, 2022 Mar Biomolecules 12

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T 

Hartrampf PE, Weinzierl FX, Serfling SE, Pomper MG, Rowe SP, Higuchi T, Seitz AK, Kübler H, Buck AK, Werner RA, 2022 Feb Cancers 14

An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy 

Mease RC, Kang CM, Kumar V, Banerjee SR, Minn I, Brummet M, Gabrielson KL, Feng Y, Park A, Kiess AP, Sgouros G, Vaidyanathan G, Zalutsky MR, Pomper MG, 2022 Feb Journal of Nuclear Medicine 63 259-267

The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy 

Dong L, Su Y, Zhu Y, Markowski MC, Xin M, Gorin MA, Dong B, Pan J, Pomper MG, Liu J, Pienta KJ, Xue W, Rowe SP, 2022 Feb Journal of Nuclear Medicine 63 248-252

A Unique Core–Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects 

Cheng B, Ahn HH, Nam H, Jiang Z, Gao FJ, Minn I, Pomper MG, 2022 Feb Pharmaceutics 14

68Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent 

Duan X, Cao Z, Zhu H, Liu C, Zhang X, Zhang J, Ren Y, Liu F, Cai X, Guo X, Xi Z, Pomper MG, Yang Z, Fan Y, Yang X, 2022 Feb European Journal of Nuclear Medicine and Molecular Imaging 49 1030-1040

Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT 

Mihatsch PW, Beissert M, Pomper MG, Bley TA, Seitz AK, Kübler H, Buck AK, Rowe SP, Serfling SE, Hartrampf PE, Werner RA, 2022 Jan Cancers 14

First-in-human use of 11C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor 

Coughlin JM, Du Y, Lesniak WG, Harrington CK, Brosnan MK, O’Toole R, Zandi A, Sweeney SE, Abdallah R, Wu Y, Holt DP, Hall AW, Dannals RF, Solnes L, Horti AG, Pomper MG, 2022 EJNMMI Research 12

High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL 

Werner RA, Habacha B, Lütje S, Bundschuh L, Higuchi T, Hartrampf P, Serfling SE, Derlin T, Lapa C, Buck AK, Essler M, Pienta KJ, Eisenberger MA, Markowski MC, Shinehouse L, Abdallah R, Salavati A, Lodge MA, Pomper MG, Gorin MA, Bundschuh RA, Rowe SP, 2022 Molecular Imaging 2022

Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET 

Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, Weich A, Pomper MG, Wester HJ, Zehndner A, Schirbel A, Samnick S, Hacker M, Pichler V, Hahner S, Fassnacht M, Einsele H, Serfling SE, Werner RA, 2022 Journal of Nuclear Medicine 63 1687-1692

Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy 

Mena E, Rowe SP, Shih JH, Lindenberg L, Turkbey B, Fourquet A, Lin FI, Adler S, Eclarinal P, McKinney YL, Citrin DE, Dahut W, Wood BJ, Chang R, Levy E, Merino M, Gorin MA, Pomper MG, Pinto PA, Eary JF, Choyke PL, Pienta KJ, 2022 Journal of Nuclear Medicine 63 1184-1190

In Vivo Functional Assessment of Sodium-Glucose Cotransporters (SGLTs) Using [18F]Me4FDG PET in Rats 

Matsusaka Y, Chen X, Arias-Loza P, Werner RA, Nose N, Sasaki T, Rowe SP, Pomper MG, Lapa C, Higuchi T, 2022 Molecular Imaging 2022

Molecular Imaging-Derived Biomarker of Cardiac Nerve Integrity — Introducing High NET Affinity PET Probe 18F-AF78 

Chen X, Werner RA, Koshino K, Nose N, Mühlig S, Rowe SP, Pomper MG, Lapa C, Decker M, Higuchi T, 2022 Theranostics 12 4446-4458

Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer 

Voter AF, Werner RA, Pienta KJ, Gorin MA, Pomper MG, Solnes LB, Rowe SP, 2022 Expert Review of Anticancer Therapy 22 681-694

Molecular Imaging in Multiple Myeloma—Novel PET Radiotracers Improve Patient Management and Guide Therapy 

von Hinten J, Kircher M, Dierks A, Pfob CH, Higuchi T, Pomper MG, Rowe SP, Buck AK, Samnick S, Werner RA, Lapa C, 2022 Frontiers in Nuclear Medicine 2

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET 

Leung KH, Rowe SP, Leal JP, Ashrafinia S, Sadaghiani MS, Chung HW, Dalaie P, Tulbah R, Yin Y, VanDenBerg R, Werner RA, Pienta KJ, Gorin MA, Du Y, Pomper MG, 2022 EJNMMI Research 12